Vishal Manchanda
Long/short equity, Deep Value, special situations, contrarian

Sell Ranbaxy And Buy AstraZeneca: Good Chance Nexium Generic Launch Delayed

Ranbaxy (OTC:RBXZF) stock is up 30 percent from the new lows it created last month. This time the rally is in expectation of superlative gains from launch of Nexium generics expected in May 27 2014 (as per settlement agreement with AstraZeneca (NYSE:AZN) ). In 2013, Nexium generated $2.1b in annual sales and the street is widely expecting Ranbaxy to reap a bonanza ($250m in incremental profits) as it has a first to file 180-days exclusivity on it.

But I feel investors are missing on the details and are being carried away as

1) There is a strong chance that Ranbaxy may not be able to launch Nexium Generics timely and in that case AstraZeneca would be...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details